-
A 48-year-old woman, who is 8 years post-hysterectomy for excessive menstrual bleeding, just completed a four-cycle course of chemotherapy (doxorubicin and cyclophosphamide), for a 2.8 cm, high-grade breast cancer with a negative sentinel node biopsy.
-
An 84-year-old community-dwelling retired physician who maintains an active lifestyle and regularly attends community hospital meetings and lectures is seen for advice regarding management. He has a longstanding history of mild hypertension currently controlled by diet and hydrochlorothiazide.
-
Potentially operable patients with Stage I non-small cell lung cancer who were treated with stereotactic ablative radiotherapy (SABR) between 1993-2010 were retrospectively identified in a prospectively collected database. Despite the median age of 76 years and the median comorbidity score of 2 in these 177 potentially operable patients, the 3-year survival was 85%. Post-SABR 30-day mortality was 0%, while predicted 30-day mortality for a lobectomy, derived using the Thoracoscore predictive model, would have been 2.6%. Local control at 3 years was 93%.
-
Host-related immunoproliferation may contribute to the pathogenesis of certain clonal myeloid disorders such as myelofibrosis and myelodysplasia.
-
Two very recent publications address the management of newly diagnosed multiple myeloma. In the first, two bortezomib-containing three-drug regimens proved equally effective as a more complex four-drug regimen in achieving meaningful initial responses. The second demonstrated the value of maintenance lenalidomide for achieving longer progression-free survival.
-
The patient is a 56-year-old woman with known meningioma first resected in 1999 followed by external beam irradiation. In 2005, she developed progressive right leg weakness and had a second operation and course of radiation.
-
The practice of tanning by artificial means, such as by sunlamps or sunbeds, continues to be popular, particularly in young people despite the acknowledged risk for increased skin cancer.
-
Drug shortages; metformin and cancer prevention; migraine prevention guidelines; and FDA actions.
-
-
Ipilimumab has recently been approved for the treatment of advanced melanoma. The current trial was undertaken to determine its safety and efficacy in patients with brain involvement.